Venetoclax-Decitabine in Untreated Elderly/Unfit AML

NARecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2027

Conditions
AML, Adult
Interventions
DRUG

VEN + DEC

"Induction regimen~Venetoclax (VEN): Day1-10~Decitabine (DEC):20mg/m²/day, Day 2-4~20mg/m² every 8 hours, Day 5-6~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14~Post-Remission Treatment~Venetoclax (VEN): 400 mg/day, Day 1-7~Decitabine (DEC): 20 mg/m² every 8 hours, Day 2-3 (Regimen repeated every 4-6 weeks)~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14"

Trial Locations (1)

Unknown

RECRUITING

The Second Hospital of Hebei Medical University, Hebei

All Listed Sponsors
collaborator

Handan First Hospital

OTHER

lead

The Second Hospital of Hebei Medical University

OTHER